Stryker Corporation (NYSE:SYK) Stock Has Average Price Target of $370.68 According to Analysts

13 Oct 2026, 05:58 by Sarita Garza · The Markets Daily

Stryker Corporation (NYSE:SYK – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-four ratings firms that are presently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $369.00.

SYK has been the topic of several research reports. Argus set a $370.00 price objective on shares of Stryker in a report on Thursday, July 9th. Citizens Jmp lowered their target price on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a report on Monday, August 3rd. Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Piper Sandler cut their price target on Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Finally, Truist Financial reduced their price target on Stryker from $340.00 to $310.00 and set a “hold” rating for the company in a research report on Tuesday, October 6th.

View Our Latest Stock Analysis on SYK

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 300,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the sale, the director directly owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the sale, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 351,267 shares of company stock worth $118,197,701 over the last quarter. Insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of SYK. State Street Corp grew its holdings in Stryker by 2.1% in the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after purchasing an additional 311,507 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Stryker by 0.6% in the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock worth $2,571,357,000 after purchasing an additional 45,478 shares in the last quarter. Bank of America Corp DE purchased a new position in Stryker during the 2nd quarter worth $1,404,284,000. Royal Bank of Canada grew its stake in Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after buying an additional 199,863 shares during the last quarter. Finally, Auto Owners Insurance Co grew its stake in Stryker by 35,047.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock worth $1,024,444,000 after buying an additional 2,906,448 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 1.9%

NYSE SYK opened at $282.61 on Friday. Stryker has a one year low of $267.00 and a one year high of $392.55. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The company has a market capitalization of $108.40 billion, a price-to-earnings ratio of 29.29, a price-to-earnings-growth ratio of 1.75 and a beta of 0.78. The company’s 50-day simple moving average is $303.25 and its two-hundred day simple moving average is $313.89.

Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter in the prior year, the company earned $3.13 EPS. The company’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts forecast that Stryker will post 14.96 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Stryker Company Profile

(Get Free Report)

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used in hospitals, surgical centers and other healthcare settings. Founded in 1941 by Dr. Homer Stryker in Kalamazoo, Michigan, the company has grown from an orthopedic device business into a diversified provider of medical technologies.